PEP (Post-Exposure Prophylaxis) – Dolutegravir + Tenofovir + Emtricitabine

Post-Exposure Prophylaxis (PEP) is a short-term treatment designed to prevent HIV infection after a potential exposure. The most effective regimen includes dolutegravir (an integrase inhibitor) plus tenofovir and emtricitabine (antiretroviral drugs).
PEP must be started within 72 hours of exposure — the sooner, the better — and continued for 28 days.
It works by blocking the virus from multiplying and spreading in the body’s immune cells.
PEP is commonly prescribed after unprotected sex, needle accidents, or occupational exposure.
Side effects may include nausea or fatigue, but they usually subside after completion.
PEP is a life-saving emergency measure and should always be prescribed and monitored by a healthcare professional.